Efficacy and safety of secukinumab in patients with rheumatoid arthritis: A phase II, dose-finding, double-blind, randomised, placebo controlled study

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 863-869

  Genovese, Mark C ^a   Durez, Patrick ^b   Richards, Hanno B ^c   Supronik, Jerzy ^d   Dokoupilova, Eva ^e   Mazurov, Vadim ^f   Aelion, Jacob A ^g   Lee, Sang Heon ^h   Codding, Christine E ⁱ   Kellner, Herbert ^j   Ikawa, Takashi ^k   Hugot, Sophie ^c   Mpofu, Shephard ^c  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NZOZ Center for Medical Genetics   (Poland)

^e Medical Plus ^*  (Czech Republic)

^f NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^g Arthritis Clinic   (United States)

^h Konkuk University Hospital   (South Korea)

ⁱ Health Research of Oklahoma   (United States)

^j Hospital Neuwittelsbach   (Germany)

^k Konan Yamate Clinic   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HIGH SENSITIVITY C REACTIVE PROTEIN; METHOTREXATE; PLACEBO; RHEUMATOID FACTOR; SECUKINUMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLECYSTITIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIP OSTEOARTHRITIS; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PYELONEPHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; THORAX DISEASE; THROMBOCYTE COUNT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-17; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84877603562     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201601     Document Type: Article

References (25)

1. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008;26:S35-61.
2. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009;11:229.
3. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002;29:2521-4. (Pubitemid 35416955)
4. Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med 2010;25:1-17.
5. Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence 2009;3:335-44.
6. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:549-53.
7. Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14:155-74. (Pubitemid 36389528)
8. Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macrophages. J Immunol 1998;160:3513-21. (Pubitemid 28164746)
9. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proin flammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-603. (Pubitemid 26193037)
10. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52. (Pubitemid 29218305)
11. Chabaud M, Lubberts E, Joosten L, et al. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3:168-77. (Pubitemid 32303433)
12. Cai L, Yin JP, Starovasnik MA, et al. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 2001;16:10-21. (Pubitemid 34925821)
13. Witowski J, Ksiazek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 2004;61:567-79. (Pubitemid 38372911)
14. Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010;62:2876-85.
15. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003;48:594-601. (Pubitemid 36301993)
16. Nakae S, Nambu A, Sudo K, et al. Suppression of immune einduction of collageninduced arthritis in Il-17 deficient mice. J Immunol 2003;171:6173-7. (Pubitemid 37467240)
17. Bush KA, Farmer KM, Walker JS, et al. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with IL-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002;46:802-5. (Pubitemid 34214263)
18. Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen induced arthritis reduces joint inflammation, cartilage destruction and bone erosion. Arthritis Rheum 2004;50:650-9. (Pubitemid 38198849)
19. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52-72.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
21. Hochberg MC, Chang RW, Dwosh I, et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
22. Tak PP, Durez P, Gomez-Reino JJ, et al. AIN457, an anti-IL-17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind, proof-of-concept trial. Ann Rheum Dis 2009;68(Suppl. 3):125.
23. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-98.
24. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39:327-46.
25. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)